Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
59 hedge funds and large institutions have $52.8M invested in Viracta Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 8 closing their positions.
167% more call options, than puts
Call options by funds: $627K | Put options by funds: $235K
19% more capital invested
Capital invested by funds: $44.2M → $52.8M (+$8.52M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 17
6% less funds holding
Funds holding: 63 → 59 (-4)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$4.21M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$877K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$620K |
| 4 |
BlackRock
New York
|
+$509K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$106K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$720K |
| 2 |
Millennium Management
New York
|
-$703K |
| 3 |
Goldman Sachs
New York
|
-$367K |
| 4 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
-$151K |
| 5 |
LSA
Leonteq Securities AG
Zurich,
Switzerland
|
-$116K |
VIRX Hedge Fund Activity: Q3 2022 in Review
59 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q3 2022, worth a combined $52.8M — up 19% from $44.2M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of VIRX and 4 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 16 added.
The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $4.21M. The largest seller was Adage Capital Partners, cutting an estimated $720K.
- 59 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q3 2022, down from 63 in Q2 2022.
- Funds reported $52.8M of Viracta Therapeutics, Inc. Common Stock stock for Q3 2022, up 19% quarter-over-quarter.
- 4 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q3 2022 and 8 closed out, a net change of -4 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q3 2022 was Rubric Capital Management (New York), an estimated $4.21M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q3 2022 was Adage Capital Partners, an estimated $720K sold.
Based on aggregated 13F filings for Q3 2022.